CDEK
← All organizations

Taro Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: ROACO | TARO | TARO PHARM | Taro Pharmaceuticals | Taro Pharmaceuticals Inc | Taro Pharmaceuticals, Inc. | TARO PHARMACEUTICALS INC | Taro Pharmaceuticals USA | Taro Pharmaceuticals USA Inc. | TARO PHARMA USA INC | TARO PHARM INDS | TARO PHARM INDS LTD | TARO PHARMS | TARO PHARMS IRELAND | TARO PHARMS NORTH

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Dec 1, 2005

First marketed drug

Feb 28, 1977

First NDA

Feb 28, 1977

Last known activity

Jun 20, 2024

Acquired by Sun Pharmaceuticals on Jan 19, 2024

Timeline

1950s

  1. Jul 1, 1950

    Taro Pharmaceuticals— Founded

1970s

  1. Feb 28, 1977

    desoximetasone— NDA Organization

2000s

  1. Aug 20, 2004

    loratadine— NDA Secondary Org

2010s

  1. Apr 15, 2011

    imiquimod— Marketing Organization

  2. Mar 17, 2017

    Thallion Pharmaceuticals— Acquired

2020s

  1. Jan 19, 2024

    Sun PharmaceuticalsSun Pharmaceuticals— Acquired By

Drugs by trial phase (34 distinct, 78 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 3 (3 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (114)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Haifa, IL Jul 1, 1950
First NDA
Feb 28, 1977
Last known activity
Jun 20, 2024